JO
NBRV

John Overdeck’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

John Overdeck’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-685
Closed -$226K – 4099
2019
Q4 		$226K Buy
685
+279
+69% +$128K ﹤0.01% 3361
2019
Q3 		$203K Buy
+406
New +$229K ﹤0.01% 3188
2019
Q2 		– Sell
-502
Closed -$306K – 3823
2019
Q1 		$306K Buy
502
+271
+117% +$148K ﹤0.01% 2587
2018
Q4 		$84K Sell
231
-261
-53% -$140K ﹤0.01% 2830
2018
Q3 		$332K Buy
+492
New +$349K ﹤0.01% 2708

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FNC
First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

John Overdeck's NBRV Position: Q1 2020 in Review

John Overdeck sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 685 shares — an estimated $226K sold.

John Overdeck first reported a position in NBRV in Q3 2018 and held it in 5 quarters. The position peaked at $332K in Q3 2018. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

  • John Overdeck reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
  • John Overdeck sold 685 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $226K.
  • John Overdeck first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2018 and held it in 5 quarters.
  • John Overdeck's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $332K in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Two Sigma Investments's 13F filing for Q1 2020, filed 15 May 2020.